# FIVE PRIME THERAPEUTICS, INC.

FIVE PRIME THERAPEUTICS, INC. is a company headquartered in South San Francisco, CA, United States.

## Company overview

- **Legal name:** FIVE PRIME THERAPEUTICS, INC.
- **Former names in filing history:** FIVE PRIME THERAPEUTICS INC (2002-05-28 to 2019-08-02)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** South San Francisco, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001175505

## About

FIVE PRIME THERAPEUTICS, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001175505, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2021-03-22, it reported annual revenue of USD 13,178,000; net income of USD -84,328,000; total assets of USD 331,650,000 for the fiscal period ended 2020-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2020 (period ended 2020-12-31)

- **Revenue:** $13.2M (USD 13,178,000)
- **Net income:** -$84.3M (USD -84,328,000)
- **Total assets:** $331.6M (USD 331,650,000)
- **Cash and equivalents:** $69.4M (USD 69,422,000)
- **Operating cash flow:** -$64.7M (USD -64,654,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $14.9M (USD 14,874,000)
- **Net income:** -$137.2M (USD -137,202,000)
- **Total assets:** $224.1M (USD 224,142,000)
- **Cash and equivalents:** $55.8M (USD 55,800,000)
- **Operating cash flow:** -$113.9M (USD -113,866,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $49.9M (USD 49,868,000)
- **Net income:** -$140.4M (USD -140,447,000)
- **Total assets:** $321.5M (USD 321,534,000)
- **Cash and equivalents:** $44.0M (USD 43,953,000)
- **Operating cash flow:** -$122.5M (USD -122,514,000)

### FY2017 (period ended 2017-12-31)

- **Net income:** -$150.2M (USD -150,222,000)
- **Total assets:** $344.0M (USD 344,047,000)
- **Cash and equivalents:** $59.8M (USD 59,790,000)

## Recent SEC filings

- Form 8-K — filed 2021-04-16 — period 2021-04-15 — 8-K
- Form 8-K — filed 2021-04-15 — period 2021-04-15 — 8-K
- Form 10-K — filed 2021-03-22 — period 2020-12-31 — 10-K
- Form SC 13D — filed 2021-03-15 — SC 13D
- Form 8-K — filed 2021-03-04 — period 2021-03-04 — 8-K
- Form SC 13G — filed 2021-03-01
- Form SC 13G — filed 2021-02-16 — SC 13G
- Form SC 13G — filed 2021-02-16
- Form SC 13G — filed 2021-02-02
- Form SC 13G — filed 2021-02-01
- Form 8-K — filed 2021-01-15 — period 2021-01-15 — 8-K
- Form 8-K — filed 2021-01-15 — period 2021-01-15 — 8-K

---

Updated: 2026-10-23T20:13:49Z

Canonical page: https://altss.com/profile/five-prime-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology